| Grenier, Julien |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery |
|
|
| Recruiting | 3 | 250 | Europe, Japan | Carboplatin, Paclitaxel | ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission | Ovarian Cancer | 06/27 | 06/28 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 52 | Europe | Pembrolizumab Injection, MK3475, neoadjuvant EC-paclitaxel chemotherapy, Epirubicine, Cyclophosphamide, Paclitaxel | Institut Paoli-Calmettes, MSD France, Oncodistinct | Inflammatory Breast Cancer | 08/22 | 08/27 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
| Recruiting | 2 | 90 | Europe | Trastuzumab + Paclitaxel, Pegfilgrastim, Neulasta | Centre Leon Berard, Amgen | HER2-positive Breast Cancer, Operable Breast Cancer | 01/25 | 09/25 | | |
| Active, not recruiting | 2 | 53 | Europe | Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo® | UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 04/25 | 04/26 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 2 | 66 | Europe | Tucatinib in Combination of Oral VP16 and trastuzumab | Institut Curie, Seagen Inc. | HER2-positive Breast Cancer | 12/26 | 12/27 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer |
|
|
| Recruiting | N/A | 327 | Europe, RoW | | ARCAGY/ GINECO GROUP | Ovarian Cancer | 12/24 | 12/24 | | |
FEGALA, NCT06379880: Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution |
|
|
| Recruiting | N/A | 506 | Europe | CONTINUUM+ CONNECT remote monitoring | Institut de cancérologie Strasbourg Europe, Continuum Plus Santé, Plateforme nationale qualité de vie et cancer, WeShare | Prostatic Neoplasms, Lung Neoplasms, Breast Neoplasms, Colorectal Neoplasms | 11/24 | 02/25 | | |
ABLE02, NCT04354233: A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 244 | Europe | Physical activity intervention with connected devices | Centre Leon Berard, Fondation ARC, Janssen, LP | Metastatic Breast Cancer | 06/24 | 06/25 | | |
| Not yet recruiting | N/A | 450 | Europe | ctDNA monitoring, 68Ga-FAPI-46-PET-CT | Institut Curie, National Research Agency, France, Roche Pharma AG | Triple Negative Breast Cancer | 12/26 | 12/28 | | |
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study |
|
|
| Recruiting | N/A | 250 | Europe | | ARCAGY/ GINECO GROUP, Institut Curie | Metastatic Endometrial Cancer | 12/24 | 12/24 | | |
| DESMOULINS, Isabelle |
| Active, not recruiting | 3 | 603 | Europe | Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing | Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform | Soft Tissue Sarcoma | 12/23 | 10/25 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
| Active, not recruiting | 2 | 147 | Europe | Durvalumab, MEDI4736, Stereotactic Body Radiotherapy, SBRT, Oleclumab, MEDI9447 | Jules Bordet Institute, Institut Curie, AstraZeneca | Luminal B | 05/25 | 09/29 | | |
| Completed | 2 | 127 | Europe | Regorafenib, stivarga, Placebo | Centre Oscar Lambret | Metastatic Soft Tissue Sarcoma | 03/24 | 09/24 | | |
| Recruiting | 2 | 119 | Europe | Association of pembrolizumab + cabozantinib | Institut Bergonié, Ipsen, MSD France | Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic Sarcoma | 04/24 | 10/25 | | |
| Recruiting | 2 | 80 | Europe | Bintrafusp alfa, Doxorubicin | Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | 09/24 | 03/25 | | |
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour |
|
|
| Not yet recruiting | 2 | 198 | Europe | Doxorubicin, Trabectedin, Yondelis | UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole | Leiomyosarcoma Uterus | 12/29 | 12/30 | | |
| Active, not recruiting | 2 | 53 | Europe | Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo® | UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 04/25 | 04/26 | | |
ETIC-LM, NCT05800275: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease |
|
|
| Recruiting | 2 | 30 | NA | Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection | UNICANCER, Seagen Inc. | Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer | 12/26 | 06/27 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
OncoSNIPE, NCT04548960: - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients |
|
|
| Recruiting | N/A | 600 | Europe | cancer patients | Oncodesign SA | CANCER | 12/21 | 03/23 | | |
| Recruiting | N/A | 34 | Europe | Blood samples, Localized sarcoma, Metastatic sarcoma | Centre Georges Francois Leclerc | Sarcoma | 11/24 | 11/25 | | |
HORMONOVILLE, NCT04142476: Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer |
|
|
| Active, not recruiting | N/A | 133 | Europe | interview | Centre Georges Francois Leclerc | Breast Cancer | 08/24 | 08/24 | | |
CHACRY-1501, NCT02871167: Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation |
|
|
| Active, not recruiting | N/A | 140 | Europe | Controlled ovarian hyperstimulation (COH), Oocyte/embryo freezing | Centre Oscar Lambret, University Hospital, Lille, National Cancer Institute, France, University Hospital, Montpellier | Breast Cancer | 12/24 | 12/25 | | |
COMPLIANCE, NCT04176809: Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer |
|
|
| Recruiting | N/A | 342 | Europe | Routine Assessment of HRQoL coupled with Therapeutic Information | Centre Georges Francois Leclerc | Breast Cancer | 04/25 | 10/25 | | |
| Active, not recruiting | N/A | 25 | Europe | Patient treated by Avapritinib in real life | Centre Leon Berard, Blueprint Medicines Corporation | GIST, GIST, Malignant, PDGFR-Alpha D842V | 04/24 | 12/24 | | |
| Deng, Yanhong |
OPTICAL, NCT02572141: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Active, not recruiting | 3 | 738 | RoW | Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens, Oxaliplatin, 5-Fluorouracil, Capecitabine, Leucovorin, Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens | Sun Yat-sen University | Colon Cancer | 04/21 | 04/23 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
TRIBE-C, NCT04230187: Bevacizumab Plus MFOLFOXIRI As First-line Treatment for Patients with Unresectable Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab | Yanhong Deng | Colorectal Cancer | 01/24 | 06/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
FOBEAR, NCT04215731: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 500 | RoW | Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX | Yanhong Deng | Rectal Cancer | 02/26 | 02/26 | | |
| Recruiting | 3 | 638 | RoW | mFOLFOXIRI adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6 adjuvant chemotherapy | Sun Yat-sen University | Colorectal Cancer | 02/25 | 02/25 | | |
AFFORD, NCT05427669: Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 340 | NA | mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6 | Yanhong Deng | Colorectal Cancer | 07/25 | 07/27 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT05130021: A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 130 | RoW | MAX-40279-01, regorafenib | Maxinovel Pty., Ltd. | Metastatic Colorectal Cancer | 05/22 | 10/23 | | |
PCOX, NCT03638297: PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer |
|
|
| Recruiting | 2 | 29 | RoW | PD-1 antibody + cox inhibitor | Sun Yat-sen University | Colorectal Cancer | 08/22 | 08/25 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT04030260: Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Regorafenib and PD-1 antibody in Combination with Radiotherapy, Regorafenib, PD-1 antibody, Radiation therapy | Sun Yat-sen University | Colorectal Cancer Metastatic, MSS | 02/23 | 07/23 | | |
PICC, NCT03926338: Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 150 | RoW | Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months | Sun Yat-sen University | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 04/27 | 04/30 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
SINCERE, NCT05933980: Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 44 | RoW | Rego+Tori+Cele, Bayer AG, Innovent Biologics | Sun Yat-sen University | Colorectal Cancer, Liver Metastases, MSS | 09/25 | 12/25 | | |
| Recruiting | 2 | 23 | RoW | Dostarlimab, GSK4057190A, TSR-042 | GlaxoSmithKline | Neoplasms, Rectal | 12/28 | 03/31 | | |
NCT05472948: Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | Surufatinib, SULANDA, Sintilimab, IBI308, Capecitabine, Capecitabine tablets | Sun Yat-sen University | Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic | 11/24 | 11/25 | | |
| Recruiting | 2 | 52 | RoW | Tislelizumab + Capecitabine, Best supportive care | Yanhong Deng | Metastatic Colorectal Cancer，NED | 02/25 | 11/27 | | |
OPTICAL-2, NCT05571644: Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 143 | RoW | mFOLFOXIRI + Cadonilimab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Cadonilimab (AK104), mFOLFOX6, mFOLFOXIRI | Sun Yat-sen University | Colorectal Cancer | 12/24 | 12/25 | | |
DETECT, NCT05578287: RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 29 | RoW | Anti-HER2 ADC, Disitamab Vedotin, Tislelizumab, Capecitabin, Celecoxib | Sun Yat-sen University | Colorectal Cancer | 12/24 | 12/25 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CEIL, NCT05959356: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 198 | RoW | Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab or c225, Envafolimab, Irinotecan, Oxaliplatin, Leucovorin, 5-FU, Cetuximab + mFOLFOX6/FOLFIRI | Sun Yat-sen University | Metastatic Colorectal Cancer | 12/25 | 12/27 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05775900: Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer |
|
|
| Recruiting | 1/2 | 24 | RoW | Cetuximab, Erbitux, Capecitabine, Capecitabine Tablets | Sun Yat-sen University | Metastatic Colorectal Cancer | 12/24 | 12/24 | | |
| Not yet recruiting | 1/2 | 74 | RoW | Liposomal irinotecan, Bevacizumab, avastin | Sun Yat-sen University | Colorectal Cancer | 06/25 | 07/26 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 28 | RoW | Cadonilimab | Sun Yat-sen University | Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) | 07/25 | 07/27 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT04930354: ECP-1014 Treatment for Patients With Solid Tumor Cancers |
|
|
| Recruiting | 1 | 29 | RoW | ECP-1014, GIBH-1014 | Euclises Pharmaceuticals, Inc. | Solid Tumor | 09/23 | 12/23 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
NCT06036862: Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis |
|
|
| Recruiting | N/A | 50 | RoW | Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction | Sun Yat-sen University | Anastomotic Stenosis | 12/26 | 12/26 | | |
NCT06043999: Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients |
|
|
| Recruiting | N/A | 392 | RoW | Radical total mesorectal excision, Salavge Adjuvant Chemoradiotherapy | Sun Yat-sen University | Chemotherapy Effect, Rectal Cancer | 12/28 | 12/28 | | |
| Zhou, Jianying |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment |
|
|
| Not yet recruiting | 2 | 40 | NA | Almonertinib, HS-10296 | Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer, EGFR Gene Mutation | 01/24 | 01/24 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
| Recruiting | 1/2 | 284 | RoW | APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | 08/25 | 08/26 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 04/26 | 04/27 | | |
FLOURISH, NCT04391283: First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting |
|
|
| Active, not recruiting | N/A | 500 | RoW | Osimertinib, TAGRISSO | First Affiliated Hospital of Zhejiang University, AstraZeneca | Carcinoma, Non-Small-Cell Lung | 04/22 | 12/24 | | |
|
NCT04153097: Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC |
|
|
| Recruiting | N/A | 500 | RoW | | First Affiliated Hospital of Zhejiang University | Non-small Cell Lung Cancer | 12/23 | 12/24 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
| Yang, Yi |
NCT04739592: A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis |
|
|
| Recruiting | 4 | 60 | RoW | alendronate sodium vitamin D3 tablets, Placebo | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Knee Osteoarthritis | 07/23 | 07/24 | | |
NCT06645522: Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke |
|
|
| Not yet recruiting | 4 | 1200 | RoW | Edaravone dexborneol, Placebo | Yi Yang | Acute Ischemic Stroke | 10/26 | 01/27 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
